Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Usage Information

Antibodies to T cells in patients with systemic lupus erythematosus can induce antibody-dependent cell-mediated cytotoxicity against human T cells.
S Kumagai, A D Steinberg, I Green
S Kumagai, A D Steinberg, I Green
View: Text | PDF
Research Article

Antibodies to T cells in patients with systemic lupus erythematosus can induce antibody-dependent cell-mediated cytotoxicity against human T cells.

  • Text
  • PDF
Abstract

Patients with active systemic lupus erythematosus (SLE) often have circulating antibodies to T cells. These patients also often have leukopenia and diminished numbers of T lymphocytes. In addition, certain T lymphocyte functions are frequently impaired in patients with SLE. It has been previously considered that a complement-dependent cytotoxic mechanism was responsible for the above observations. We now demonstrate that antibody-dependent cell-mediated cytotoxicity (ADCC), a cytotoxic reaction mediated by antibody and effector cells in the absence of complement, can also kill T cells from normal individuals as well as from patients with SLE. Moreover, this ADCC could be observed using the plasma, effector cells, and target cells all obtained from the same individual with SLE. Plasma of those patients with active SLE, and in whom anti-T cell antibodies could be demonstrated by the more classical complement-dependent cytotoxicity, was most often able to mediate such an ADCC reaction. The IgG fraction of the plasma was responsible for inducing ADCC, and aggregated IgG could block the reaction. The fact that the IgG fraction was often more effective than the unfractionated plasma suggested that immune complexes present in SLE plasma might partially block the expression of ADCC. Because a single SLE plasma could induce ADCC in T cells from several different unrelated individuals, it is unlikely that antibodies directed against particular human leukocyte antigens (HLA) or blood group antigens are involved.

Authors

S Kumagai, A D Steinberg, I Green

×

Usage data is cumulative from November 2025 through November 2026.

Usage JCI PMC
Text version 374 27
PDF 173 10
Scanned page 857 2
Citation downloads 209 0
Totals 1,613 39
Total Views 1,652
(Click and drag on plot area to zoom in. Click legend items above to toggle)

Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.

Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.

Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts